
Cat. #161737
anti-TPX2 [TPX2-01]
Cat. #: 161737
Sub-type: Primary antibody
Availability: 3-4 weeks
Target: TPX2
Class: Monoclonal
Application: IHC(P), IP, ELISA, WB, ICC
Reactivity: Human; Mouse
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Pavel DrĂĄber
Institute: Institute of Molecular Genetics of the Czech Academy of Sciences
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: anti-TPX2 [TPX2-01]
- Research fields: Cell biology
- Clone: TPX2-01
- Tool sub type: Primary antibody
- Class: Monoclonal
- Conjugation: Unconjugated
- Reactivity: Human; Mouse
- Host: Mouse
- Application: IHC(P), IP, ELISA, WB, ICC
- Description: Antibody to TPX2 microtuble nucleation factor
- Isotype: IgG1
Target Details
- Target: TPX2
- Epitope sequence: 622-662
Applications
- Application: IHC(P), IP, ELISA, WB, ICC
Handling
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Dry ice
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)



